While the threat of tariffs dies down for the pharma industry, President Donald Trump is reportedly weighing a new investigation that could result in import taxes against U.S. trading partners that don’t pay enough for drugs.
Trump To Target Trading Partners With Drug Pricing Probe: Report Read More »
The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in infectious disease and other oncology indications.
Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody Read More »
Health technology firms are interested in going public next year, but policy and economic uncertainty creates a difficult environment for IPOs, experts said at HLTH.
Digital health IPO window opens, but uncertainty clouds outlook Read More »
La neurocirugía es una de las ramas más complejas y fascinantes de la medicina moderna. En las últimas décadas, los avances tecnológicos, la investigación científica y la experiencia acumulada por los grandes especialistas han transformado p …
Seven in 10 U.S. hiring managers say their company usually considers employing overqualified applicants, according to a survey from Express Employment Professionals and The Harris Poll. However, 75% of employers believe such hires struggle to stay motivated in lower-level roles.
Most Employers Consider Hiring But Worry About Overqualified Job Candidates: Survey Read More »
This represents Alector’s second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in Alzheimer’s last November. On latozinemab for frontotemporal dementia, Alector was working with GSK, which fronted $700 million in 2021 to collaborate on two programs.
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff Read More »
For $1.2 billion upfront and up to $10.2 billion in milestones, Takeda will gain access to a bispecific antibody fusion protein targeting both the PD-1 and IL-2 pathways, among other assets.
Takeda Bets Up to $11.4B For Three Innovent ADCs Read More »
Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN-601.
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile Read More »
Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ESMO, with antibody-drug conjugates, bispecific antibodies and kinase inhibitors demonstrating encouraging efficacy and safety for various cancers.
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin Read More »
Nunca antes se había identificado de forma definitiva un individuo juvenil de Pleurosaurus, un reptil marino del Jurásico que vivió hace unos 150 millones de años. Un equipo internacional de paleontólogos ha descrito por primera vez un ejemplar post-eclosi …
Hallan el primer ejemplar juvenil de Pleurosaurus Read More »
